Good doctors: safer patients--the Chief Medical Officer's prescription for regulating doctors

Rovere, G. Querci della; McCartney, Margaret; Thornton, Hazel

doi:10.1258/jrsm.99.11.545

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The implementation of the current-sector wide COI guidance by individual trusts, and how it might have been affected by their institutional cultures and policies, has not been investigated in relation to institutional COIs. However, compliance with the guidelines in relation to publishing individual-level COI declarations has been described as poor [121] or not always consistent across the studied trusts [122]. In addition, gaps in the reporting of joint working projects with drug companies suggest that at least some trusts lack a complete picture of their financial ties with external organisations [38].…”

Section: Plos Onementioning

confidence: 98%

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database

Ozieranski,

Saghy,

Mulinari

2023

PLoS ONE

View full text Add to dashboard Cite

Introduction Although hospitals are key health service providers, their financial ties to drug companies are little understood. We examine non-research pharmaceutical industry payments to English National Health Service (NHS) trusts—hospital groupings providing secondary and tertiary care. Methods We extracted data from the industry-run Disclosure UK database, analysing it descriptively and using the Jonckheere-Terpstra test to establish whether a statistically significant time trend existed in the median values of individual payments. We explained payment value and number per trust with random effects models, using selected trust characteristics as predictors. Results Drug companies reported paying £60,253,421 to 234 trusts, representing between 90.0% and 92.0% of all trusts in England between 2015 and 2018. As a share of payments to all healthcare organisations, the number of payments rose from 38.6% to 39.5%, but their value dropped from 33.0% to 23.6%. The number of payments for fees for service and consultancy and contributions to costs of events increased by 61.5% and 29.4%. The median payment value decreased significantly for trusts overall (from £2,250.8 to £1,758.5), including those with lower autonomy from central government; providing acute services; and from half of England’s regions. The random effects model showed that acute trusts received significantly more money on average than trusts with all other service profiles; and trusts from East England received significantly less than those from London. However, trusts enjoying greater autonomy from government did not receive significantly more money than others. Trusts also received significantly less money in 2018 than in 2015. Conclusion NHS trusts had extensive pharmaceutical industry ties but were losing importance as payment targets relative to other healthcare organisations. Industry payment strategies shifted towards events sponsorship, consultancies, and smaller payments. Trusts with specific service and geographical profiles were prioritised. Understanding corporate payments across the health system requires more granular disclosure data.

show abstract

Section: Plos Onementioning

confidence: 98%